Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase " I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
0.0028 | |
0.0028 | |
- | |
0.0028 | |
0.0028 | |
0.0028-0.0443 | |
3 048 K | |
1 088 M | |
0 | |
4.126 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: